论文部分内容阅读
目的观察吉西他滨(商品名健择)联合顺铂化疗治疗晚期原发性肝癌的疗效及毒副反应。方法34例失去手术机会的晚期肝癌患者,给予GP方案化疗四个周期,观察其疗效及毒副反应。结果CR 1例、PR 9例,MR10例,SD8例,PD6例,RR 29．4%(10/34)。45．8%(11/24)的病人AFP较治疗前基线下降超过50%。21例疗前有肝区疼痛的患者,疼痛全部于化疗两个周期后消失。不良反应主要为骨髓抑制,Ⅲ-Ⅳ度白细胞减少为17．6%(6/34),Ⅲ-Ⅳ度血小板减少为14．7%(5/34);非血液学毒性方面,除少数病人有轻度恶心外,胆红素、转氨酶升高均不超过正常值上限1．5倍,尿素氮、肌酐未发现有明显升高。临床获益患者中位TTP4．5个月,MST12．8个月,一年生存率60．7%。结论GP方案化疗治疗晚期肝癌具有较好的客观疗效,副反应轻,能明显减轻病人的痛苦,延长病人的生命,值得进—步探讨、研究。
Objective To observe the curative effect and toxicity of gemcitabine (product of Jianzheng) combined with cisplatin in the treatment of advanced primary liver cancer. Methods Thirty - four patients with advanced liver cancer who lost their chances of surgery were given four cycles of GP regimen and the curative effect and toxicity were observed. Results CR 1, PR 9, MR 10, SD 8, PD 6, RR 29.4% (10/34). 45.8% (11/24) of patients AFP dropped more than 50% from baseline before treatment. Twenty-one patients with hepatic pain prior to treatment had all their pain disappeared after two cycles of chemotherapy. The main adverse reactions were myelosuppression, grade Ⅲ-Ⅳ leukopenia was 17.6% (6/34), and grade Ⅲ-Ⅳ thrombocytopenia was 14.7% (5/34). For non-hematologic toxicity, With mild nausea, bilirubin, elevated transaminases were not more than 1.5 times the upper limit of normal, urea nitrogen, creatinine was not significantly increased. The median clinical benefit of TTP4.5 months, MST12.8 months, one-year survival rate of 60.7%. Conclusion GP regimen chemotherapy for advanced liver cancer has a good objective effect, mild side effects, can significantly reduce the patient’s suffering and prolong the life of the patient, it is worth further exploration and research.